<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26243660</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2015</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.</ArticleTitle><Pagination><StartPage>12973</StartPage><MedlinePgn>12973</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12973</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep12973</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major etiological agents of hand, foot and mouth disease (HFMD) and are often associated with neurological complications. Currently, several vaccine types are being developed for EV71 and CA16. In this study, we constructed a bivalent chimeric virus-like particle (VLP) presenting the VP1 (aa208-222) and VP2 (aa141-155) epitopes of EV71 using hepatitis B virus core protein (HBc) as a carrier, designated HBc-E1/2. Immunization with the chimeric VLPs HBc-E1/2 induced higher IgG titers and neutralization titers against EV71 and CA16 in vitro than immunization with only one epitope incorporated into HBc. Importantly, passive immunization with the recombinant HBc-E2 particles protected neonatal mice against lethal EV71 and CA16 infections. We demonstrate that anti-VP2 (aa141-155) sera bound authentic CA16 viral particles, whereas anti-VP1 (aa208-222) sera could not. Moreover, the anti-VP2 (aa141-155) antibodies inhibited the binding of human serum to virions, which demonstrated that the VP2 epitope is immunodominant between EV71 and CA16. These results illustrated that the chimeric VLP HBc-E1/2 is a promising candidate for a broad-spectrum HFMD vaccine, and also reveals mechanisms of protection by the neighboring linear epitopes of the VP1 GH and VP2 EF loops.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Longfa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Delei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhiqun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiangzhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, 102206, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuxuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lunzhi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Hongliu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical College, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Que</LastName><ForeName>Yuqiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo Shih</LastName><ForeName>James Wai</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, New Jersey Medical School, Rutgers University, 225 Warren Street, Newark, NJ 070101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yimin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, 102206, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ningshao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen 361102, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26243660</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pii">srep12973</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan L. G. et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31, 678&#x2013;683 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C. C., Tseng H. W., Wang S. M., Wang J. R. &amp; Su I. J. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17, 23&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26, 91&#x2013;107 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10, 778&#x2013;790 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright H. T. Jr., Landing B. H., Lennette E. H. &amp; Mc A. R. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 268, 1041&#x2013;1044 (1963).</Citation><ArticleIdList><ArticleId IdType="pubmed">14001956</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K. et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis 15, 1689&#x2013;1691 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau H. F., Richter M. &amp; Doerr H. W. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199, 45&#x2013;51 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 22, 781&#x2013;792 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246273</ArticleId><ArticleId IdType="pubmed">21968769</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F. et al. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol J 8, 508 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227625</ArticleId><ArticleId IdType="pubmed">22054534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F. C. et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381, 2024&#x2013;2032 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. P. et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis 209, 46&#x2013;55 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenyu W. et al. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis 210, 1073&#x2013;1082 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24625805</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R. et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 370, 829&#x2013;837 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F. et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370, 818&#x2013;828 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Wang H., Shih S. R., Chen T. C. &amp; Li M. L. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr Med Chem 14, 847&#x2013;856 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17430140</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D. G. et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125, 61&#x2013;68 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G. H. et al. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 7, 106 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q. &amp; Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 31, 2130&#x2013;2136 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C. C. et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29, 4362&#x2013;4372 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H. et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci Rep 5, 7878 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L. et al. Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop. Theranostics 4, 498&#x2013;513 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Ku Z., Liu Q., Leng Q. &amp; Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32, 2406&#x2013;2412 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D. G., Alonso S., Chow V. T. &amp; Poh C. L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9, 1299&#x2013;1306 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19, 424&#x2013;429 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho S. Y. et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 76, 111&#x2013;119 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223651</ArticleId><ArticleId IdType="pubmed">17954727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X. et al. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 7, e41381 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407240</ArticleId><ArticleId IdType="pubmed">22848478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X. et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88, 72&#x2013;81 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T. K. et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J 9, 55 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W. et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 9, 8 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev A. N. Role of recombination in evolution of enteroviruses. Rev Med Virol 15, 157&#x2013;167 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15578739</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S., Maher K. &amp; Pallansch M. A. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes. J Virol 78, 855&#x2013;867 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368751</ArticleId><ArticleId IdType="pubmed">14694117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A., Tagaya I. &amp; Yoneyama T. Common antigen between coxsackievirus A 16 and enterovirus 71. Microbiol Immunol 22, 81&#x2013;88 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">209293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T. C. et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 81, 10310&#x2013;10315 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045469</ArticleId><ArticleId IdType="pubmed">17626076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M. et al. Cryo-EM study of insect cell-expressed Enterovirus 71 and Coxsackievirus A16 virus-like particles provides a structural basis for vaccine development. J Virol 88, 6444&#x2013;6452 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J. et al. Picornavirus uncoating intermediate captured in atomic detail. Nat Commun 4, 1929 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K. L. et al. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9, e1003240 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>